The global cardiovascular drugs market, a part of the healthcare industry, declined at a compound annual growth rate (CAGR) of around -0.1% during the historic period. The healthcare industry showed a decline. The decline in the market is due to patent expiries of a major brands of cardiovascular drugs such as Lipitor, Plavi and others. Loss of patency has increased the market scope for generic versions of the drug with a huge difference in the prices.
In the forecast period, the global cardiovascular drugs market size is expected to be over $65 billion by 2021, growing at a CAGR of nearly 2%. This is expected due to the increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment. Furthermore, rising population, increase in dispensable income, and increasing per capita incomes are expected to drive the global cardiovascular drugs market in the future.
Find TBRC’s report on the cardiovascular drugs market: https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report-2018
The Food and Drug Administration (FDA) in the USA has approved new drugs for treatment of chronic heart failure. Chronic heart failure is a cardiovascular disorder caused by an inadequate cardiac output (ability of the heart to pump blood)
Major companies in the cardiovascular drugs market, offering FDA technology include Merck & Co., Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly And Company, Johnson & Johnson, AstraZeneca Plc., Abbott Laboratories Inc., Bayer AG.
Download a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=271&type=smp
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
In the forecast period, the global cardiovascular drugs market size is expected to be over $65 billion by 2021, growing at a CAGR of nearly 2%. This is expected due to the increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment. Furthermore, rising population, increase in dispensable income, and increasing per capita incomes are expected to drive the global cardiovascular drugs market in the future.
Find TBRC’s report on the cardiovascular drugs market: https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report-2018
The Food and Drug Administration (FDA) in the USA has approved new drugs for treatment of chronic heart failure. Chronic heart failure is a cardiovascular disorder caused by an inadequate cardiac output (ability of the heart to pump blood)
Major companies in the cardiovascular drugs market, offering FDA technology include Merck & Co., Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly And Company, Johnson & Johnson, AstraZeneca Plc., Abbott Laboratories Inc., Bayer AG.
Download a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=271&type=smp
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
No comments:
Post a Comment